S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

$61.82
+0.42 (+0.68%)
(As of 12/8/2023 08:57 PM ET)
Compare
Today's Range
$60.51
$62.30
50-Day Range
$49.57
$61.82
52-Week Range
$49.24
$85.70
Volume
101,800 shs
Average Volume
104,565 shs
Market Capitalization
$1.07 billion
P/E Ratio
90.91
Dividend Yield
N/A
Price Target
$109.75

Ligand Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
77.5% Upside
$109.75 Price Target
Short Interest
Bearish
5.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
-0.08mentions of Ligand Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$237,520 Bought Last Quarter
Proj. Earnings Growth
-28.50%
From $4.21 to $3.01 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

87th out of 942 stocks

Pharmaceutical Preparations Industry

23rd out of 424 stocks


LGND stock logo

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

LGND Stock Price History

LGND Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Ligand Pharmaceuticals: A Complicated Tale
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
Ligand Pharmaceuticals: Q3 Earnings Insights
Ligand Pharmaceuticals Inc Q3 Earnings Summary
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call
Ligand Reports Third Quarter 2023 Financial Results
See More Headlines
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$109.75
High Stock Price Target
$144.00
Low Stock Price Target
$90.00
Potential Upside/Downside
+77.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-33,360,000.00
Pretax Margin
46.03%

Debt

Sales & Book Value

Annual Sales
$196.24 million
Cash Flow
$5.12 per share
Book Value
$35.37 per share

Miscellaneous

Free Float
15,550,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
0.92
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Todd C. Davis Ph.D. (Age 62)
    CEO & Director
    Comp: $743.49k
  • Mr. Matthew E. Korenberg (Age 48)
    President & COO
    Comp: $760.99k
  • Mr. Octavio Espinoza (Age 52)
    Chief Financial Officer
    Comp: $457.19k
  • Mr. Andrew T. Reardon J.D. (Age 48)
    Chief Legal Officer & Secretary
    Comp: $480.16k
  • Simon Latimer
    Head of Investor Relations
  • Mr. Todd Pettingill
    Director of Corporate Development
  • Ms. Audrey Warfield-Graham
    Chief People Officer
  • Dr. Keith Marschke
    Senior Vice President of Biology & Scientific Affairs
  • Dr. Vincent D. Antle (Age 54)
    Senior Vice President of Technical Operations & QA - Capitsol
  • Mr. Patrick Lucy
    Senior VP & CBO Protein Expression Business














LGND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued twelve-month price targets for Ligand Pharmaceuticals' shares. Their LGND share price targets range from $90.00 to $144.00. On average, they predict the company's share price to reach $109.75 in the next year. This suggests a possible upside of 77.5% from the stock's current price.
View analysts price targets for LGND
or view top-rated stocks among Wall Street analysts.

How have LGND shares performed in 2023?

Ligand Pharmaceuticals' stock was trading at $66.80 on January 1st, 2023. Since then, LGND stock has decreased by 7.5% and is now trading at $61.82.
View the best growth stocks for 2023 here
.

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our LGND earnings forecast
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported $1.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.34. The biotechnology company earned $32.87 million during the quarter, compared to analyst estimates of $27.22 million. Ligand Pharmaceuticals had a net margin of 9.09% and a trailing twelve-month return on equity of 9.67%. The firm's quarterly revenue was down 44.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided EPS guidance of $5.25-5.40 for the period, compared to the consensus estimate of $5.04. The company issued revenue guidance of $126-129 million, compared to the consensus revenue estimate of $126.51 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Villere ST Denis J & Co. LLC (2.53%), Chicago Capital LLC (2.08%), abrdn plc (1.85%), Rice Hall James & Associates LLC (1.63%), Northern Trust Corp (1.27%) and Invesco Ltd. (1.26%). Insiders that own company stock include Andrew Reardon, Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis.
View institutional ownership trends
.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LGND) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -